American Century Companies Inc. Takes $195,000 Position in Aratana Therapeutics Inc (NASDAQ:PETX)

American Century Companies Inc. acquired a new stake in shares of Aratana Therapeutics Inc (NASDAQ:PETX) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 45,942 shares of the biopharmaceutical company’s stock, valued at approximately $195,000. American Century Companies Inc. owned 0.10% of Aratana Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. boosted its stake in shares of Aratana Therapeutics by 23.8% during the first quarter. Schwab Charles Investment Management Inc. now owns 90,100 shares of the biopharmaceutical company’s stock valued at $398,000 after purchasing an additional 17,300 shares during the period. Franklin Resources Inc. boosted its stake in shares of Aratana Therapeutics by 0.5% during the first quarter. Franklin Resources Inc. now owns 5,969,371 shares of the biopharmaceutical company’s stock valued at $26,325,000 after purchasing an additional 28,969 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Aratana Therapeutics by 30.5% during the first quarter. Dimensional Fund Advisors LP now owns 785,096 shares of the biopharmaceutical company’s stock valued at $3,462,000 after purchasing an additional 183,294 shares during the period. Massachusetts Financial Services Co. MA boosted its stake in shares of Aratana Therapeutics by 36.2% during the second quarter. Massachusetts Financial Services Co. MA now owns 1,376,198 shares of the biopharmaceutical company’s stock valued at $5,849,000 after purchasing an additional 365,750 shares during the period. Finally, Wells Fargo & Company MN boosted its stake in shares of Aratana Therapeutics by 38.5% during the first quarter. Wells Fargo & Company MN now owns 639,436 shares of the biopharmaceutical company’s stock valued at $2,820,000 after purchasing an additional 177,824 shares during the period. 65.44% of the stock is owned by hedge funds and other institutional investors.

PETX stock traded up $0.02 on Friday, reaching $5.77. The company’s stock had a trading volume of 138,115 shares, compared to its average volume of 369,266. Aratana Therapeutics Inc has a 12-month low of $3.67 and a 12-month high of $7.28. The firm has a market capitalization of $278.40 million, a price-to-earnings ratio of -5.95 and a beta of 2.37. The company has a quick ratio of 2.44, a current ratio of 3.02 and a debt-to-equity ratio of 0.09.

Aratana Therapeutics (NASDAQ:PETX) last announced its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. Aratana Therapeutics had a negative return on equity of 35.25% and a negative net margin of 154.23%. The company had revenue of $4.91 million during the quarter, compared to analyst estimates of $4.72 million. Equities research analysts anticipate that Aratana Therapeutics Inc will post -0.48 earnings per share for the current year.

A number of analysts have recently weighed in on the company. BidaskClub lowered Aratana Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. Zacks Investment Research raised Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 price objective for the company in a research note on Tuesday, September 11th. ValuEngine raised Aratana Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 15th. Finally, Stifel Nicolaus dropped their price objective on Aratana Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Monday, August 6th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $7.96.

In other Aratana Therapeutics news, CEO Peter Steven St sold 75,000 shares of the firm’s stock in a transaction on Friday, September 21st. The stock was sold at an average price of $6.06, for a total transaction of $454,500.00. Following the completion of the transaction, the chief executive officer now owns 574,233 shares of the company’s stock, valued at $3,479,851.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ernst Heinen sold 10,372 shares of the firm’s stock in a transaction on Tuesday, August 14th. The shares were sold at an average price of $5.15, for a total value of $53,415.80. Following the transaction, the insider now directly owns 157,406 shares of the company’s stock, valued at approximately $810,640.90. The disclosure for this sale can be found here. Insiders sold 104,187 shares of company stock valued at $595,372 in the last ninety days. 5.30% of the stock is currently owned by insiders.

Aratana Therapeutics Profile

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.

See Also: What is an Initial Public Offering (IPO)?

Institutional Ownership by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply